Immunometabolic Profile of Nigerian COVID-19 Patients
Abstract
Objective: Existence of crosstalk between metabolic and immune response against severe, acute respiratory syndrome coronavirus 2 (SARS-CoV-2) indicates that its full understanding could facilitate therapeutic insights for Coronavirus disease 2019 (COVID-19) management. Therefore, selected immunometabolic indices were determined in COVID-19 patients at a Nigerian Isolation Centre.
Material and Methods: Haematological parameters (Total White Blood Cell [TWBC] and Differential White Blood Cell Counts), inflammation indices (C-Reactive Protein [CRP], Albumin, Pre-albumin and Neutrophil/Lymphocyte ratio [NLR]), anti-SARS-CoV-2 specific immunoglobulin (Ig) M and IgG, respiratory burst factors, lipid profile as well as renal and liver functions were determined in COVID-19 patients and controls.
Results: Seventy percent of the COVID-19 patients were less than 40 years of age and largely had mild COVID-19. The mean TWBC, neutrophil, NLR and CRP levels were significantly higher, while the lymphocyte count was significantly lower in COVID-19 patients compared with the controls. Also, the mean plasma levels of anti-SARS-CoV-2 specific IgG and IgM in addition to superoxide dismutase (SOD) activity were significantly higher, while the mean plasma levels of nitric oxide, hydrogen peroxide and myeloperoxidase activity were significantly lower in COVID-19 patients compared with the controls. High proportions of COVID-19 patients had values of the liver (59%-96%) and renal (43%-97%) function test parameters within the normal reference intervals. Similarly, high proportions of COVID-19 patients had values of lipid profile (71%-86%) within the normal reference intervals.
Conclusion: The infrequent alteration in lipid metabolism as well as liver and renal functions suggest mild COVID-19. However, hyper-inflammation remains a significant observation in COVID-19 patients, irrespective of the form of the disease.
Keywords
Full Text:
PDFReferences
Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell 2021;184:861-80.
Zhou X, Ye Q. Cellular immune response to COVID-19 and potential immune modulators. Front Immunol 2021;12:646333.
Fathi F, Sami R, Mozafarpoor S, Hafezi H, Motedayyen H, Arefnezhad R, et al. Immune system changes during COVID-19 recovery play key role in determining disease severity. Int J Immunopathol Pharmacol 2020;34. doi: 10.1177/ 2058738420966497.
Thaker SK, Ch’ng J, Christofk HR. Viral hijacking of cellular metabolism. BMC Biol 2019;17:1-15.
Moreno-Altamirano MMB, Kolstoe SE, Sánchez-García FJ. Virus control of cell metabolism for replication and evasion of host immune responses. Front Cell Infect Microbiol 2019;9:95.
Lucas C, Wong P, Klein J, Castro TB, Silva J, Sundaram M, et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature 2020;584:463-9.
Siska PJ, Decking S-M, Babl N, Matos C, Bruss C, Singer K, et al. Metabolic imbalance of T cells in COVID-19 is hallmarked by basigin and mitigated by dexamethasone. J Clin Invest 2021;131:e148225.
Kumar V. How could we forget immunometabolism in SARSCoV2 infection or COVID-19? Int Rev Immunol 2021;40:72-107.
Herrera-Van Oostdam AS, Castañeda-Delgado JE, Oropeza- Valdez JJ, Borrego JC, Monárrez-Espino J, Zheng J, et al. Immunometabolic signatures predict risk of progression to sepsis in COVID-19. PLoS One 2021;16:e0256784.
O’Carroll SM, O’Neill LAJ. Targeting immunometabolism to treat COVID-19. Immunother Adv 2021;1:ltab013. doi: 10.1093/ immadv/ltab013.
World Health Organization. Laboratory testing strategy recommendations for COVID-19 [homepage on the Internet]. New Delhi: WHO Regional Office for South-East Asia; 2020 [cited 2022 Sep 10]. Available from: https://apo.who.int/publications/i/ item/laboratory-testing-strategy-recommendations-for-covid- 19-interim-guidance
Edem V, Arinola O. Leucocyte migration and intracellular killing in newly diagnosed pulmonary tuberculosis patients and during anti-tuberculosis chemotherapy. Ann Glob Health 2015;81: 669-74.
Iwasaki A, Yang Y. The potential danger of suboptimal antibody responses in COVID-19. Nat Rev Immunol 2020;20:339-41.
Pang NY-L, Pang AS-R, Chow VT, Wang D-Y. Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice. Mil Med Res 2021;8:1-17.
Mardani R, Vasmehjani AA, Zali F, Gholami A, Nasab SDM, Kaghazian H, et al. Laboratory parameters in detection of COVID-19 patients with positive RT-PCR; a diagnostic accuracy study. Arch Acad Emerg Med 2020;8:e43.
Lagunas-Rangel FA. Neutrophil-to-lymphocyte ratio and lymphocyte-to-C-reactive protein ratio in patients with severe coronavirus disease 2019 (COVID-19): a meta-analysis. J Med Virol 2020;92:1733-34.
Sun S, Cai X, Wang H, He G, Lin Y, Lu B, et al. Abnormalities of peripheral blood system in patients with COVID-19 in Wenzhou, China. Clin Chim Acta 2020;507:174-80.
Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020;8:420-2.
Yao XH, Li TY, He ZC, Ping YF, Liu HW, Yu SC, et al. A pathological report of three COVID-19 cases by minimal invasive autopsies. Zhonghua Bing Li Xue Za Zhi 2020;49:411-7.
Galani IE, Andreakos E. Neutrophils in viral infections: current concepts and caveats. J leukoc Biol 2015;98:557-64.
Prince LR, Whyte MK, Sabroe I, Parker LC. The role of TLRs in neutrophil activation. Curr Opin Pharmacol 2011;11:397-403.
Abd El-Lateef AE, Ismail MM, Thabet G, Cabrido N-A. Complete blood cells count abnormalities in COVID-19 patients and their prognostic significance: single center study in Makkah, Saudi Arabia. Saudi Med J 2022;43:572-8.
Chen J, Qi T, Liu L, Ling Y, Qian Z, Li T, et al. Clinical progression of patients with COVID-19 in Shanghai, China. J Infect 2020;80:e1-6.
Aratani Y, Miura N, Ohno N, Suzuki K. Role of neutrophil-derived reactive oxygen species in host defense and inflammation. Med Mycol J 2012;53:123-8.
Yoo SK, Huttenlocher A. Innate immunity: wounds burst H2O2 signals to leukocytes. Curr Biol 2009;19:R553-5.
Ignarro LJ. Inhaled NO and COVID-19. Brit J Pharmacol 2020;177:3848.
Lopes-Pacheco M, Silva PL, Cruz FF, Battaglini D, Robba C, Pelosi P, et al. Pathogenesis of multiple organ injury in COVID-19 and potential therapeutic strategies. Front Physiol 2021;12:593223.
Cai Q, Huang D, Yu H, Zhu Z, Xia Z, Su Y, et al. COVID-19: Abnormal liver function tests. J Hepatol 2020;73:566-74.
Zhang Y, Zheng L, Liu L, Zhao M, Xiao J, Zhao Q. Liver impairment in COVID-19 patients: A retrospective analysis of 115 cases from a single centre in Wuhan city, China. Liver Int 2020;40:2095-103.
Rismanbaf A, Zarei S. Liver and kidney injuries in COVID-19 and their effects on drug therapy; a letter to editor. Arch Acad Emerg Med 2020;8:e17.
Li D, Ding X, Xie M, Tian D, Xia L. COVID-19-associated liver injury: from bedside to bench. J Gastroenterol 2021;56:218-30.
Andrade Silva M, da Silva ARPA, do Amaral MA, Fragas MG, Câmara NOS. Metabolic alterations in SARS-CoV-2 infection and its implication in kidney dysfunction. Front Physiol 2021;12:624698.
Wu D, Shu T, Yang X, Song JX, Zhang M, Yao C, et al. Plasma metabolomic and lipidomic alterations associated with COVID-19. Natl Sci Rev 2020;7:1157-68.
Beck FK, Rosenthal TC. Prealbumin: a marker for nutritional evaluation. Am Fam Physician 2002;65:1575.
Keller U. Nutritional laboratory markers in malnutrition. J Clin Med 2019;8:775.
Myron Johnson A, Merlini G, Sheldon J, Ichihara K. Clinical indications for plasma protein assays: transthyretin (prealbumin) in inflammation and malnutrition. Clin Chem Lab Med 2007;45: 419-26.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506.
Huang J, Cheng A, Kumar R, Fang Y, Chen G, Zhu Y, et al. Hypoalbuminemia predicts the outcome of COVID-19 independent of age and co-morbidity. J Med Virol 2020;92: 2152-8.
Arinola GO, Edem FV, Alonge TO. Levels of plasma C-reactive protein, albumin and pre-albumin in Nigerian COVID-19 Patients. Ann Med Res 2022;29:46-51.
Anderson R, Schmidt R. Clinical biomarkers in sepsis. Front Biosci (Elite Ed) 2010;2:504-20.
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.